Jennifer Marie Suga, MD, discusses implementing a genomic oncology program at Kaiser Permanente Northern California through large-scale genomic next generation sequencing testing of patients with advanced cancers in the community setting.
Jennifer Marie Suga, MD, a medical oncologist at Kaiser Permanente Vallejo Medical Center, discusses implementing a genomic oncology program at Kaiser Permanente Northern California through large-scale genomic next generation sequencing (NGS) testing of patients with advanced cancers in the community setting.
Suga says that the goals of this project are to address how to increase the utilization of NGS testing and make it more widespread in community oncology practices. One of the practical challenges for testing in the community setting is lack of access at scale; many health care systems and institutions do not have a lot of robust infrastructure and processes to deliver routine broad-spectrum NGS testing for all patients with advanced cancer, according to Suga.
Employing this comprehensive genomic oncology program will hopefully support community oncologists from the time they ordered the test up to when they receive the results to ultimately increase the utilization of NGS in the community setting, Suga explains. To implement this program, Kaiser Permanente partnered with Strata Oncology, who provided a form through their clinical trials protocol for Kaiser to provide the NGS test for community practices. After that, they will work toward implementing a process for ordering the test all the way through interpretation and results.
<< View more of Targeted Oncology's coverage from the 2020 ASCO Virtual Annual Meeting
Advancing Neoadjuvant Therapy for HER2+ Breast Cancer Through ctDNA Monitoring
December 19th 2024In an interview with Targeted Oncology, Adrienne Waks, MD, provided insights into the significance of the findings from the DAPHNe trial and their clinical implications for patients with HER2-positive breast cancer.
Read More
Imlunestrant Improves PFS in ESR1-Mutant Advanced Breast Cancer
December 13th 2024The phase 3 EMBER-3 trial showed imlunestrant improved PFS over SOC endocrine therapy in ER-positive, HER2-negative advanced breast cancer with ESR1 mutations, though not significantly in the overall population.
Read More
ctDNA Detection Tied to Tumor Burden, Recurrence in HR+ Early Breast Cancer
December 13th 2024A phase 2 trial showed ctDNA detection in HR-positive early breast cancer was linked to larger tumors, higher residual cancer burden, and increased recurrence after neoadjuvant endocrine therapy.
Read More